XW00X27
Introduction Skin to New Technology Group 7 with Anacaulase-bcdb, External Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | 0 Skin |
| Approach | X External |
| Device | 2 Anacaulase-bcdb |
| Qualifier | 7 New Technology Group 7 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Skin
Skin is the body's outermost anatomical region, and Introduction procedures targeting it under New Technology involve placing a substance directly into or onto this layer for a therapeutic effect not achieved through standard topical or subcutaneous administration. Because skin varies in thickness, vascularity, and barrier function across body sites, the intended depth and distribution of the introduced substance affect both technique and outcome. This code category is used for novel biologic or pharmacologic agents delivered specifically to the dermal or epidermal layer, distinguishing it from injections into deeper subcutaneous tissue. Documentation should reflect that the skin itself, rather than an underlying structure, was the treated site, since accurate body part selection depends on where the substance was actually introduced.
Approach: External
External approach in New Technology applies to procedures performed directly on the skin, mucous membranes, or via direct visualization without penetrating a body cavity, such as applying or activating a device against the body surface. It contrasts with Percutaneous approaches, which require instrument entry through the skin rather than surface-level contact.
Device / Substance / Technology: Anacaulase-bcdb
Anacaulase-bcdb is a topical enzymatic debridement agent derived from bromelain, used to selectively remove eschar and dead tissue from burn wounds without excising healthy surrounding skin. It offers a nonsurgical alternative to mechanical or surgical debridement, reducing the need for repeated tangential excision in appropriate burn injuries. It is distinguished from monoclonal antibodies and antineoplastics in this list by its enzymatic, topical mechanism rather than a systemic immunologic one.
Qualifier: New Technology Group 7
As a qualifier value, Group 7 marks a code as belonging to the set of new technologies approved for use in the 2020-2021 fiscal year, a period that included a notable expansion of infectious-disease-related add-on codes. The label does not describe what the technology does; that detail sits in the table and other axis values. It is distinguished from adjoining groups solely by its approval-year cohort.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.